 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AVC-201 / AvenCell Therap
Enrollment change, Trial completion date, Trial primary completion date: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (clinicaltrials.gov) - Feb 12, 2025
P1, N=80, Recruiting, Sponsor: AvenCell Europe GmbH
N=37 --> 80 | Trial completion date: Jun 2026 --> Jan 2028 | Trial primary completion date: Dec 2025 --> May 2027
- | AVC-201 / AvenCell Therap
Trial completion date, Trial primary completion date: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (clinicaltrials.gov) - Apr 30, 2024
P1, N=37, Recruiting, Sponsor: AvenCell Europe GmbH
N=37 --> 80 | Trial completion date: Jun 2026 --> Jan 2028 | Trial primary completion date: Dec 2025 --> May 2027 Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
- || AVC-201 / AvenCell Therap
Enrollment open, Trial initiation date: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (clinicaltrials.gov) - Feb 5, 2024
P1, N=37, Recruiting, Sponsor: AvenCell Europe GmbH
Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025 Not yet recruiting --> Recruiting | Initiation date: Aug 2023 --> Jan 2024
- AVC-201 / AvenCell Therap
Functional Characterization and Optimization of Switchable Allogeneic Chimeric Antigen Receptor T Cells for Targeting CD19 and CD20 in B Cell Malignancies (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_2493;
P1
A summary of functional characterization data will be presented at the meeting with a focus on the lack of predictability of certain in vitro models and underlying hypotheses. Insights from these studies are now flowing into preclinical development of a novel switchable allogeneic CAR-T cell product candidate targeting CD19 and CD20 in B cell malignancies engineered to fully overcome graft-versus-host disease as well as graft rejection by host T and NK cells.
- || AVC-201 / AvenCell Therap
New P1 trial: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (clinicaltrials.gov) - Jul 17, 2023
P1, N=37, Not yet recruiting, Sponsor: AvenCell Europe GmbH